Fighting the Impact of COVID-19 with Serology Testing

New IgG and IgM tests could identify people with COVID-19 antibodies, which may help reduce social and economic impacts of the outbreak. Learn more.
Fighting the Impact of COVID-19 with Serology Testing

Antibody testing may be a vital tool for determining who has developed an immune response to SARS-Cov-21 thus allowing to better quantify the number of cases of COVID-19, including those that may be asymptomatic or have recovered.2

The U.S. Food and Drug Administration has said there are multiple use cases for serological tests:3

  • They could help decide whether people who are found to be immune can return to work
  • They could determine the people who may qualify for a vaccination once it is available
  • They could identify people who have recovered to see if they can donate plasma that may be used as a treatment for people with severe forms of the disease caused by the novel coronavirus

What is serology testing?

A serology test detects the presence of antibodies, which are specific proteins called immunoglobulins made by the body in response to infections. The body makes different types of immunoglobulins to fight different types of infections. This means that an antibody for chickenpox, for example, will not be the same for SARS-CoV-2.

Serology testing for SARS-CoV-2

In response to the coronavirus, manufacturers are producing tests to measure different types of SARS-CoV-2 antibodies, mainly immunoglobulin M (IgM) and immunoglobulin G (IgG). (Figure 1.)

How IgG and IgM Antibody Tests Work

A chart to identify how IgG and IgM antibody tests work

Figure 1. An antibody test works by detecting immune response to earlier infection.4 

IgG can be detected approximately two weeks after infection and is the type of antibody that is responsible for longer term immunity (months to years). However, researchers know very little about the immune response to SARS-CoV-2 at this time, including the degree of immunity to reinfection that may be afforded by antibodies. IgM is the first line of defense against an infection and can be detected approximately four to seven days after infection. However, it is not sustained and IgM production decreases after the onset of IgG production. There is a short window where both IgM and IgG can be detected.

How an ELISA Assay Works

A chart to demonstrate how and ELISA assay works

Figure 2. An ELISA assay works by attracting an antigen to a substrate. The antibody to the antigen is linked to an enzyme, which is then measured.5 

The benefits of serology testing for SARS-CoV-2

By integrating SARS-CoV-2 antibody testing into their routine laboratory workflow, laboratories of all sizes may be able to:

  • help reduce pressure on healthcare resources by identifying individuals who have potentially developed an immune response to SARS-CoV-2, so critical patients and patients at risk can get the care they need
  • mitigate shortage in the workforce by allowing those who have developed an immune response to safely return to work
  • help free healthcare system capacity for those who need most assistance by identifying patients who have developed an immune response
  • determine how much of the population has been exposed to help navigate the possibility of rolling reopening, need for vaccination and future disease management

The caveat is that the serology test used must be a high-quality test with the highest sensitivity and specificity, tested in a broad-based population.


What makes a SARS CoV-2 antibody test high quality?

1Olson, J. “Minnesota readies antibody COVID-19 response.” Star Tribune, Apr 14, 2020. https://m.startribune.com/minnesota-readies-antibody-covid-19-response/569595692/. Accessed on Apr 20, 2020.

2Serology-based tests for COVID-19. Johns Hopkins Bloomberg School of Public Health Center for Health Security. https://www.centerforhealthsecurity.org/resources/COVID-19/serology/Serology-based-tests-for-COVID-19.html. Accessed on Apr 20, 2020.

3Lee, J. “Testing for COVID-19 antibodies could be a ‘game changer’ for the economy but it’s still too early to tell.” MarketWatch, Apr 13, 2020. https://www.marketwatch.com/story/testing-for-covid-19-antibodies-could-be-a-game-changer-for-the-economy-but-its-still-too-early-to-tell-2020-04-08. Accessed on Apr 20, 2020.

4Cookson, C., Hodgson, C. “What coronavirus tests does the world need to track the pandemic?” Financial Times, Mar 31, 2020. https://www.ft.com/content/0faf8e7a-d966-44a5-b4ee-8213841da688. Accessed on Apr 20, 2020.

5Serology testing for COVID-19. Johns Hopkins Center for Health Security, Feb 28, 2020. https://www.centerforhealthsecurity.org/resources/COVID-19/COVID-19-fact-sheets/200228-Serology-testing-COVID.pdf. Accessed on Apr 20, 2020.

Editorial Team
Editorial Team
The Beckman Coulter editorial team brings you timely news and resources focused on elevating clinical laboratory performance and advancing patient care.

Related Articles

A New Powerful Web Search Experience

A New Powerful Web Search Experience

Beckman Coulter is thrilled to introduce a revolutionary new web search experience, empowering you to find information faster, making your searches more productive than ever before.
Bacterial Resistance: Actions from the Core Microbiology Lab

Bacterial Resistance: Actions from the Core Microbiology Lab

Learn from our MicroTeam some “MicroTips” about the critical role of the microbiology laboratory for patients, reporting, and the larger impact to antimicrobial stewardship.
Alzheimer’s disease: Challenges to diagnosis and the emerging treatment landscape

Alzheimer’s disease: Challenges to diagnosis and the emerging treatment landscape

Alzheimer's disease is the most common form of dementia. The prevalence of this debilitating disease is expected to continue to rise in the coming years as the global population ages, making it an increasingly important global public health issue.